| Phase 11 trial |
|
Phase 1
|
NCT07348042 |
Sep 2025 → Mar 2027 expected |
— |
Xian-Jun Yu |
Recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06859775 |
Apr 2025 → Oct 2026 expected |
— |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06589778 |
Sep 2024 → Apr 2026 overdue |
non-small cell lung carcinoma |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT07638852 |
Feb 2026 → Jun 2028 expected |
metastatic malignant neoplasm in the brain, triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07336979 |
Mar 2025 → Mar 2027 expected |
mucosal melanoma |
Sun Yat-sen University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06429696 |
Jul 2024 → Apr 2026 overdue |
small cell lung carcinoma |
Nanfang Hospital, Southern Medical University |
Recruiting
|
No outcome recorded
|
| Comparator or background therapy2 trials |
|
Phase 2
|
NCT06771154 Comparator |
Apr 2025 → Apr 2029 expected |
endometrial cancer |
Peking Union Medical College Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06895928 Background |
Mar 2025 → Dec 2028 expected |
cancer |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|